[1]骆鹏飞综述马伟**审校.多基因分子检测在细胞学不确定甲状腺结节中的研究进展[J].中国微创外科杂志,2026,01(3):0.
点击复制

多基因分子检测在细胞学不确定甲状腺结节中的研究进展

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2026年3期
页码:
0
栏目:
文献综述
出版日期:
2026-03-26

文章信息/Info

作者:
骆鹏飞综述马伟**审校
(安徽省阜阳市人民医院普外科，阜阳236000)
文献标志码:
A

参考文献/References:

[1]Luo P,Ma W,Jiao D.Do stylet needles improve diagnostic accuracy in thyroid fineneedle aspiration?A retrospective analysis.BMC Endocr Disord,2025,25(1):145.
[2]骆鹏飞,王雨.术中冰冻在Bethesda Ⅵ类甲状腺结节患者手术方式选择中的价值.中国微创外科杂志,2025,25(2):70-74.
[3]Ali SZ,Baloch ZW,CochandPriollet B,et al.The 2023 Bethesda system for reporting thyroid cytopathology.Thyroid,2023,33(9):1039-1044.
[4]焦琼,刘志艳.第3版甲状腺细胞病理Bethesda报告系统解读.中华医学杂志,2023,103(41):3238-3244.
[5]Vardarli I,Tan S,Grges R,et al.Diagnostic accuracy of Afirma gene expression classifier,Afirma gene sequencing classifier,ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda Ⅲ and Ⅳ) thyroid nodules:a metaanalysis.Endocr Connect,2024,13(7):e240170.
[6]San Martin VT,Lawrence L,Bena J,et al.Realworld comparison of Afirma GEC and GSC for the assessment of cytologically indeterminate thyroid nodules.J Clin Endocrinol Metab,2020,105(3):dgz099.
[7]Hannoush ZC,RuizCordero R,Jara M,et al.Current state of molecular cytology in thyroid nodules: platforms and their diagnostic and theranostic utility.J Clin Med,2024,13(6):1759.
[8]Torrecillas V,Sharma A,Neuberger K,et al.Utility of mutational analysis for risk stratification of indeterminate thyroid nodules in a realworld setting.Clin Endocrinol,2021,96(4):637-645.
[9]Bandargal S,Hier J,Abdulhaleem M,et al.Role of publiclyfunded molecular testing in surgical management of thyroid nodules within Canadian medicare:clinical assessment of ThyroSeq v3 Molecular Test Pilot Project at McGill University. J Otolaryngol Head Neck Surg,2025,54:19160216251336687.
[10]Papoian V,Rosen JE,Lee W,et al.Differentiated thyroid cancer and Hashimoto thyroiditis:utility of the Afirma gene expression classifier.J Surg Oncol,2020,121(7):1053-1057.
[11]DiGennaro C,Vahdatzad V,Jalali MS,et al.Assessing bias and limitations of clinical validation studies of molecular diagnostic tests for indeterminate thyroid nodules:systematic review and metaanalysis.Thyroid,2022,32(10):1144-1157.
[12]Chowdhury R,Hier J,Payne KE,et al.Impact of molecular testing on surgical decisionmaking in indeterminate thyroid nodules:a systematic review and metaanalysis of recent advancements.Cancers (Basel),2025,17(7):1156.
[13]Chiosea S,Hodak SP,Yip L,et al.Molecular profiling of 50 734 Bethesda ⅢⅣ thyroid nodules by ThyroSeq v3:implications for personalized management.J Clin Endocrinol Metab,2023,108(11):2999-3008.
[14]Glass RE,Marotti JD,Kerr DA,et al.Using molecular testing to improve the management of thyroid nodules with indeterminate cytology:an institutional experience with review of molecular alterations.J Am Soc Cytopathol,2021,11(2):79-86.
[15]Lévesque F,Payne RJ,Beaudoin D,et al.Publicly funded molecular testing of indeterminate thyroid nodules:Canada’s experience.J Clin Endocrinol Metab,2025,110(4):e1031-e1037.
[16]Lee E,Terhaar S,McDaniel L,et al.Diagnostic performance of the secondgeneration molecular tests in the assessment of indeterminate thyroid nodules:a systematic review and metaanalysis.Am J Otolaryngol,2022,43(3):103394.
[17]Alzahrani AS.Clinical use of molecular data in thyroid nodules and cancer.J Clin Endocrinol Metab,2023,108(11):2759-2771.
[18]Raghunathan R,Longstaff XR,Hughes EG,et al.Diagnostic performance of molecular testing in indeterminate (Bethesda Ⅲ and Ⅳ) thyroid nodules with Hürthle cell cytology.Surgery,2023,175(1):221-227.
[19]Nishino M,Mateo R,Kilim H,et al.Repeat fine needle aspiration cytology refines the selection of thyroid nodules for Afirma Gene Expression Classifier testing.Thyroid,2021,31(8):1253-1263.
[20]Alexander EK,Kennedy GC,Baloch ZW,et al.Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.N Engl J Med,2012,367(8):705-715.
[21]Kim NE,Raghunathan RS,Hughes EG,et al.Bethesda Ⅲ and Ⅳ thyroid nodules managed nonoperatively after molecular testing with Afirma GSC or Thyroseq v3.J Clin Endocrinol Metab,2023,108(9):e698-e703.
[22]Lonar I,van Velsen EFS,Massolt ET,et al.European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules:a clinical utility study in the Netherlands.Head Neck,2023,45(9):2227-2236.
[23]Sultan R,Levy S,Sulanc E,et al.Utility of Afirma Gene Expression Classifier for evaluation of indeterminate thyroid nodules and correlation with ultrasound risk assessment:single institutional experience.Endocr Pract,2020,26(5):543-551.
[24]Jin X,Lew M,Pantanowitz L,et al.Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category Ⅲ thyroid nodules.Cancer Cytopathol,2022,130(11):891-898.
[25]Jin X,Lew M,Pantanowitz L,et al.Performance of Afirma genomic sequencing classifier and histopathological outcome in Bethesda category Ⅲ thyroid nodules:initial versus repeat fineneedle aspiration.Diagn Cytopathol,2023,51(11):698-704.
[26]Patel KN,Angell TE,Babiarz J,et al.Performance of a Genomic Sequencing Classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules.JAMA Surg,2018,153(9):817-824.
[27]Geng Y,AguilarJakthong JS,Moatamed NA.Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules:a singleinstitutional experience.Cytopathology,2020,32(2):187-191.
[28]Polavarapu P,Fingeret A,YuilValdes A,et al.Comparison of Afirma GEC and GSC to nodules without molecular testing in cytologically indeterminate thyroid nodules.J Endocr Soc,2021,5(11):bvab148.
[29]Zhang L,Smola B,Lew M,et al.Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category Ⅲ thyroid nodules:an institutional experience.Diagn Cytopathol,2021,49(8):921-927.
[30]Nasr CE,Andrioli M,Endo M,et al.Realworld performance of the Afirma Genomic Sequencing Classifier (GSC):a metaanalysis.J Clin Endocrinol Metab,2023,108(6):1526-1532.
[31]Yang Z,Zhang T,Layfield L,et al.Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.J Am Soc Cytopathol,2021,11(2):74-78.
[32]Babazadeh NT,Sinclair TJ,Krishnamurthy V,et al.Thyroid nodule molecular profiling: the clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifiersuspicious results. Surgery,2022,171(1):155-159.
[33]MunozZuluaga CA,Heymann JJ,Solomon JP,et al.Use of the Afirma Xpression Atlas for cytologically indeterminate,Afirma Genomic Sequencing Classifier suspicious thyroid nodules:clinicopathologic analysis with postoperative molecular testing.Am J Clin Pathol,2024,161(5):463-468.
[34]Steinmetz D,Kim M,Choi JH,et al.How effective is the use of molecular testing in preoperative decision making for management of indeterminate thyroid nodules?World J Surg,2022,46(12):3043-3050.
[35]Nikiforova MN,Mercurio S,Wald AI,et al.Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.Cancer,2018,124(8):1682-1690.
[36]Hanba C,Khariwala SS.What is the utility of genetic testing in indeterminate thyroid nodules?Laryngoscope,2021,131(11):2399-2400.
[37]Chen T,Gilfix BM,Rivera J,et al.The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the Canadian Public Health Care Setting.Thyroid,2020,30(9):1280-1287.
[38]Steward DL,Carty SE,Sippel RS,et al.Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology:a prospective blinded multicenter study.JAMA Oncol,2019,5(2):204-212.
[39]Carty SE,Ohori NP,Hilko DA,et al.The clinical utility of molecular testing in the management of thyroid follicular neoplasms (Bethesda IV nodules).Ann Surg,2020,272(4):621-627.
[40]Desai D,Lepe M,Baloch ZW,et al.ThyroSeq v3 for Bethesda Ⅲ and Ⅳ:an institutional experience.Cancer Cytopathol,2020,129(2):164-170.
[41]Papazian MR,Dublin JC,Patel KN,et al.Repeat fineneedle aspiration with molecular analysis in management of indeterminate thyroid nodules.Otolaryngol Head Neck Surg,2023,168(4):738-744.
[42]Tjendra Y,Kerr DA,Zuo Y,et al.Probability of malignancy and molecular alterations as determined by ThyroSeq v3 genomic classifier in Bethesda Category Ⅳ.Cancer Cytopathol,2023,131(9):586-595.
[43]Sirotnikov S,Griffith CC,Lubin D,et al.ThyroSeq overview on indeterminate thyroid nodules:an institutional experience.Diagn Cytopathol,2024,52(7):353-361.
[44]Finkelstein SD,Sistrunk JW,Malchoff C,et al.A retrospective evaluation of the diagnostic performance of an interdependent pairwise microRNA expression analysis with a mutation panel in indeterminate thyroid nodules.Thyroid,2022,32(11):1362-1371.
[45]Tumati A,Egan CE,LeeSaxton YJ,et al.Clinical utility of a microRNA classifier in cytologically indeterminate thyroid nodules with RAS mutations:a multiinstitutional study.Surgery,2023,175(1):234-240.
[46]LithwickYanai G,Dromi N,Shtabsky A,et al.Multicentre validation of a microRNAbased assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears.J Clin Pathol,2017,70(6):500-507.
[47]Olmos R,Domínguez JM,VargasSalas S,et al.ThyroidPrint:clinical utility for indeterminate thyroid cytology.Endocr Relat Cancer,2023,30(11):e220409.
[48]Dharampal N,Smith K,Harvey A,et al.Costeffectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules.J Otolaryngol Head Neck Surg,2022,51(1):46.
[49]Song Y,Xu G,Ma T,et al.Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules:a prospective blinded single center study in China.Cancer Med,2020,9(22):8397-8405.
[50]Tan LC,Liu WL,Zhu XL,et al.Nextgeneration sequencing enhances the diagnosis efficiency in thyroid nodules.Front Oncol,2021,11:677892.
[51]Ding M,Wu G,Zhang S,et al.Clinical implications and application of molecular testing in the diagnosis and management of thyroid nodules in the Chinese population.Clin Cancer Res,2025,31(23):4996-5005.
[52]于风霞,牛丽娟,李卫华,等.二代测序技术检测超声引导下细针穿刺活检甲状腺微小结节标本中多基因突变及其诊断甲状腺微小癌的价值.中华医学杂志,2024,104(38):3580-3585.
[53]He S,Zhang J,Wang M,et al.Improving diagnostic accuracy of indeterminate thyroid fineneedle aspiration using results of ultrasound examination,cyclin D1 immunostaining,and molecular testing.Acta Cytol,2025,69(6):515-527.
[54]Zhang M,Hu X,Liu L,et al.Clinical value of multigene testing in distinguishing benign and malignant thyroid nodules.Medicine (Baltimore),2024,103(4):e35960.
[55]Fei M,Ding D,Ouyang X,et al.The value of NGSbased multigene testing for differentiation of benign from malignant and risk stratification of thyroid nodules.Front Oncol,2024,14:1414492.
[56]Ren M,Yao Q,Bao L,et al.Diagnostic performance of nextgeneration sequencing and genetic profiling in thyroid nodules from a single center in China.Eur Thyroid J,2022,11(3):e210124.
[57]Hu C,Jing W,Chang Q,et al. Risk stratification of indeterminate thyroid nodules by novel multigene testing:a study of Asians with a high risk of malignancy.Mol Oncol,2022,16(8):1680-1693.
[58]Xu H,Zhang Y,Wu H,et al.High diagnostic accuracy of epigenetic imprinting biomarkers in thyroid nodules.J Clin Oncol,2023,41(6):1296-1306.
[59]Yang W,Yin M,Zhou J,et al.Stepwise analysis of thyroid diagnostic modalities with genomic imprinting detection.Chin Clin Oncol,2024,13(2):21.
[60]Gortakowski M,Feghali K,Osakwe I.Single institution experience with Afirma and Thyroseq testing in indeterminate thyroid nodules.Thyroid,2021,31(9):1376-1382.
[61]Kakudo K.Asian and Western practice in thyroid pathology:similarities and differences.Gland Surg,2020,9(5):1614-1627.

备注/Memo

备注/Memo:
基金项目：安徽省卫生健康科研项目(AHWJ2024Ab0145) **通讯作者，Email：drmawei1988@163.com
更新日期/Last Update: 1900-01-01